Ex vivo liver resection and auto-transplantation as an alternative to treat liver malignancies: Progress and challenges

Hepatobiliary Pancreat Dis Int. 2023 Oct 20:S1499-3872(23)00181-9. doi: 10.1016/j.hbpd.2023.10.007. Online ahead of print.

Abstract

Hepatectomy is still the major curative treatment for patients with liver malignancies. However, it is still a big challenge to remove the tumors in the central posterior area, especially if their location involves the retrohepatic inferior vena cava (RHIVC) and hepatic veins. Ex vivo liver resection and auto-transplantation (ELRA), a hybrid technique of the traditional liver resection and transplantation, has brought new hope to these patients and therefore becomes a valid alternative to liver transplantation. Due to its technical difficulty, ELRA is still concentrated in a few hepatobiliary centers that have experienced surgeons in both liver resection and liver transplantation. The efficacy and safety of this technique has already been demonstrated in the treatment of benign liver diseases, especially in the advanced alveolar echinococcosis. Recently, the application of ELRA for liver malignances has gained more attention. However, standardization of clinical practice norms and international consensus are still lacking. The prognostic impact in these oncologic patients also needs further evaluation. In this review, we summarized the principles and recent progresses on ELRA.

Keywords: Ex vivo liver resection; Liver auto-transplantation; Liver malignancies; Oncology.

Publication types

  • Review